Open Access Full Text Article

ORIGINAL RESEARCH

Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis

Hai-Feng Ma
Guo-Xiao Lv
Zhong-Fang Cai
Da-Hai Zhang

Department of Radiotherapy,
Dongyang People's Hospital,
Dongyang, Zhejiang, China

Background: Resection remains the best treatment for carcinoma of the esophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. Chemoradiotherapy (CRT) followed by surgery was associated with significantly improved survival benefit, but the effectiveness of neoadjuvant therapy in patients with resectable esophageal carcinoma remains controversial. The aim of this study was to evaluate the effects of neoadjuvant chemoradiotherapy in resectable esophageal carcinoma compared to surgery alone (SA).

Methods: A search for publications that compared the efficacy of CRT with SA in resectable esophageal carcinoma was conducted. After a rigorous review of the quality, the data were extracted from eligible trials. The major outcomes measures were odds ratios (ORs). The ORs with their corresponding 95% confidence intervals were the principal measure of effects. For the meta-analysis, Revman 5.3 software was used to analyze the combined pooled ORs using fixed- or random-effects models according to the heterogeneity.

Results: Our findings revealed that, compared with SA, neoadjuvant CRT was associated with improved overall survival (OS) and progression-free survival times, but the 3- and 5-year OS did not show a statistical difference ($P \geq 0.05$). The adjuvant chemotherapy group did not show significant improvement on reference rate and metastasis rate compared with the control group.

Conclusion: CRT does significantly improve progression-free survival and OS in patients with esophageal cancer compared with SA. However, further assessment is still warranted on the role of CRT in future trials with well-selected patients.

Keywords: esophageal cancer, surgery, chemoradiation, neoadjuvant therapy

Introduction

Esophageal carcinoma is an aggressive malignancy of the gastrointestinal tract. Surgery has been the primary treatment for esophageal cancer; however, treatment failure results in many cases due to recurrence and distant metastases remain an issue after surgery.

Efforts have led to the investigation of multimodality therapies, and a combination of chemotherapy, radiotherapy, and surgery has been generally accepted as a reasonable option for patients with locoregional esophageal cancer.[1,2] Radiotherapy can help with local disease control, while chemotherapy may be effective for both local and systemic antineoplastic activity.

Many studies have demonstrated the effectiveness of neoadjuvant CRT, which has been shown to lead to downsizing and downstaging the tumor and improving survival.[3] However, toxic effects and compliance with protocols have hindered the development of multidisciplinary treatment.

Correspondence: Da-Hai Zhang
Department of Radiotherapy, Dongyang
People's Hospital, Number 60 West
Wuning Road, Dongyang, Zhejiang
322100, China
Tel +86 579 8685 9403
Email dyzdh@126.com

There is still controversy about how to improve prognosis and how to reduce local recurrence and distant metastasis. There has been limited information to suggest that either surgery or radiation/chemotherapy is a superior approach. This also raises the question about whether combining both would be superior to improve the postoperative quality of life and prolong the survival time. We performed this meta-analysis to assess the effect of neoadjuvant CRT on operable esophageal cancer compared to the surgery alone (SA).

Methods and materials
Search strategy
Two investigators independently searched electronic databases PubMed, Embase, and Cochrane Library up to March 2017. The process was established to find all articles with the keywords: "esophageal neoplasm" AND "chemotherapy" "radiotherapy" AND "chemo-radiotherapy" AND "surgery", and relevant Medical Subject Heading terms were utilized. The reference lists of all articles that dealt with the topic of interest were also hand-searched to check for additional relevant publications.

Eligibility criteria
Studies were included in the meta-analysis if they met the following criteria: 1) trials evaluating CRT versus SA; 2) articles that provided data on the survival between patients from the CRT and those from the SA groups; 3) articles that described the cases and controls with regard to the reference (R) rate and metastasis (M) rate; and 4) studies that provided sufficient information to estimate the odds ratio (OR) and their 95% confidence intervals (CIs). The studies not published in English were excluded.

Quality assessment
Two investigators independently rated the quality of the retrieved studies. We chose the risk of bias items recommended by The Cochrane Handbook for Systematic Reviews of Interventions as a quality indicator.

Data extraction
Two independent investigators extracted the relevant information from each study. Disagreement was revolved by consensus. From each of the eligible studies, the main categories that were extracted were as follows: first author family name, publication year, histology, treatment (size), endpoints of interest, and ORs with corresponding 95% CIs or relevant data for OR and 95% CI calculation for endpoints of interest.

Statistical analysis
The association between CRT and surgery with resected esophageal cancer is based on the data from trials. The endpoints of interest in the pooled analysis were 3-year overall survival (OS), 5-year OS, OS, progression-free survival (PFS), R data, and M data, and the endpoint outcomes were considered as a weighted average of individual estimate of the hazard ratio (HR) in every included study using the inverse variance method. If HRs and corresponding 95% CIs were reported, lnHRs and the corresponding ln lower limits and ln upper limits were used as data points in pooling analysis.

A sensitivity analysis was also performed to examine the impact on the overall results, depending on the heterogeneity across the included studies. Heterogeneity was investigated by using the I^2 statistic.[4] Studies with an I^2 of 25%–50%, 50%–75%, or >75% were considered to have low, moderate, or high heterogeneity, respectively.[5] Only if there was low heterogeneity among studies was the fixed-effects model used. Otherwise, the random-effects model was used. A P-value less than 0.05 was considered statistically significant. The statistical analyses were performed using Review Manager version 5.3 software (Revman; The Cochrane Collaboration, Oxford, UK). Findings of our meta-analysis are shown as forest plots.

Results
Overview of literature search and study characteristics
A total of 238 studies were retrieved initially for evaluation. Based on the criteria described in the methods, 10 publications were evaluated in more detail, but some did not provide data of outcomes of two approaches. Therefore, a final total of seven studies were included.[6–12] The search process is described in Figure 1.

All included studies in this study were considered to be of moderate quality at least. Table 1 describes the primary characteristics of the eligible studies in more detail.

Clinical and methodological heterogeneity
Pooled analysis of 3-year OS and 5-year OS between CRT and SA
Overall, six studies reported data on 3-year OS[6–8,10–12] and four studies reported data on 5-year OS,[7–9,12] and these are shown in Figures 2 and 3. Pooled data showed that CRT treatment did not show any benefit, with the pooled HR being 1.06 (95% CI: 0.59–1.92, Z=0.21, P=0.83) and 0.91 (95% CI: 0.44–1.89, Z=0.26, P=0.80), respectively.

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart of selection process to identify studies eligible for pooling.

Pooled analysis of OS between CRT and SA

A total of seven studies[6–12] reported the OS rates in patients (Figure 4). OS was superior in the CRT group compared with SA group (HR: 0.60, 95% CI: 0.40–0.91, $Z=2.40$, $P=0.02$).

Pooled analysis of PFS between CRT and SA

In the analysis of PFS in early-stage non-small-cell lung cancer, four studies[7,8,11,12] were included that compared CRT with surgery. These data are shown in Figure 5. The PFS (HR: 0.36, 95% CI: 0.16–0.79, $Z=2.52$, $P=0.01$) benefits were seen in the CRT treatments.

Pooled analysis of R rate and M rate between CRT and SA

R rate and M rate were available for five trials[7,9,10–12] (Figure 6) and three trials, respectively[10–12] (Figure 7). The aggregated results suggested that there was no R rate (HR: 0.35, 95% CI: 0.10–1.19, $Z=1.68$, $P=0.09$) or M rate (HR: 0.72, 95% CI: 0.50–1.04, $Z=1.73$, $P=0.08$) benefit from CRT.

Table 1 The primary characteristics of the eligible studies in more detail

Reference	Country	Histology	Treatment (n of patients) CRT+S/SA	Dose (mg/m²)	Overall survival Follow-up (mo)	Metastasis (n of patients)* Intervention	Control	Recurrence (n of patients)* Intervention	Control
Urba et al,[6] 2001	USA	SCC and AC	47/50	C:20; F:300; 35 Gy	98				12
Tepper et al,[7] 2008	USA	SCC and AC	30/26	C:100; F:1,000; 41.5 Gy	60			9	
van Hagen et al,[9] 2012	The Netherlands	SCC and AC	178/188	Carboplatin: 2 mg/mL/min; P:50; 41.4 Gy	45.4			62	188
Burmeister et al,[12] 2005	Australia	SCC and AC	128/128	C:80; F:1,800; 35 Gy	65	48	54	61	68
Lv et al,[8] 2010	China	SCC	80/80	P:135 d1, 22; C:20 d1–3 and 22–25; 40 Gy	45				
Mariette et al,[10] 2014	France	SCC	98/97	C:75 d1; F:800 d1–4; 45 Gy	93.6	22	28	28	43
Lee et al,[11] 2004	Korea	SCC	51/50	C:60; F:1,000; 45.6 Gy	25	6	12	19	18

Note: *Data was pooled from different trials with different inclusion criteria, patients might have differential criteria for metastasis and recurrence; there is significant heterogeneity among included studies.
Abbreviations: AC, adenocarcinoma; C, cisplatin; CRT, chemoradiotherapy; d, day; F, fluorouracil; mo, months; P, paclitaxel; S, surgery; SA, surgery alone; SCC, squamous cell carcinoma.

| Reference | Experimental | | Control | | Weight | OR M–H, | OR M–H, random, 95% CI |
	Events	Total	Events	Total	(%)	random, 95% CI	
Burmeister et al,[12] 2005	75	128	86	128	19.7	0.69 (0.42, 1.15)	
Lee et al,[11] 2004	38	51	31	50	15.6	1.79 (0.77, 4.19)	
Lv et al,[8] 2010	36	78	51	80	18.2	0.49 (0.26, 0.92)	
Mariette et al,[10] 2014	38	98	38	97	19.0	0.98 (0.55, 1.75)	
Tepper et al,[7] 2008	20	30	5	26	11.5	8.40 (2.44, 28.91)	
Urba et al,[6] 2001	17	47	23	50	16.0	0.67 (0.29, 1.50)	
Total (95% CI)		**432**		**431**	**100**	**1.06 (0.59, 1.92)**	
Total events	224		234				

Heterogeneity: $\tau^2=0.39$; $\chi^2=20.29$, $df=5$ ($P=0.001$); $I^2=75\%$
Test for overall effect: $Z=0.21$ ($P=0.83$)

Figure 2 Pooled analysis of 3-year OS between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; OS, overall survival; S, surgery; SA, surgery alone.

| Reference | Experimental | | Control | | Weight | OR M–H, | OR M–H, random, 95% CI |
	Events	Total	Events	Total	(%)	random, 95% CI	
Burmeister et al,[12] 2005	76	128	87	128	28.4	0.69 (0.41, 1.15)	
Lv et al,[8] 2010	43	78	58	80	26.0	0.47 (0.24, 0.90)	
Tepper et al,[7] 2008	18	30	4	26	16.3	8.25 (2.27, 30.02)	
van Hagen et al,[9] 2012	45	178	66	188	29.3	0.63 (0.40, 0.98)	
Total (95% CI)		**414**		**422**	**100**	**0.91 (0.44, 1.89)**	
Total events	182		215				

Heterogeneity: $\tau^2=0.43$; $\chi^2=15.78$, $df=3$ ($P=0.001$); $I^2=81\%$
Test for overall effect: $Z=0.26$ ($P=0.80$)

Figure 3 Pooled analysis of 5-year OS between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; OS, overall survival; S, surgery; SA, surgery alone.

| Reference | Experimental | | Control | | Weight | OR M–H, | OR M–H, random, 95% CI |
	Events	Total	Events	Total	(%)	random, 95% CI	
Burmeister et al,[12] 2005	51	128	57	128	18.8	0.83 (0.50, 1.36)	
Lee et al,[11] 2004	14	51	16	50	12.3	0.80 (0.34, 1.89)	
Lv et al,[8] 2010	50	78	75	80	10.1	0.12 (0.04, 0.33)	
Mariette et al,[10] 2014	38	98	38	97	17.2	0.98 (0.55, 1.75)	
Tepper et al,[7] 2008	7	30	12	26	8.7	0.36 (0.11, 1.12)	
Urba et al,[6] 2001	17	47	23	50	12.9	0.67 (0.29, 1.50)	
van Hagen et al,[9] 2012	48	178	68	188	19.9	0.65 (0.42, 1.02)	
Total (95% CI)		**610**		**619**	**100**	**0.60 (0.04, 0.91)**	
Total events	225		289				

Heterogeneity: $\tau^2=0.17$; $\chi^2=14.94$, $df=6$ ($P=0.02$); $I^2=60\%$
Test for overall effect: $Z=2.40$ ($P=0.02$)

Figure 4 Pooled analysis of OS between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; OS, overall survival; S, surgery; SA, surgery alone.

| Reference | Experimental | | Control | | Weight | OR M–H, | OR M–H, random, 95% CI |
	Events	Total	Events	Total	(%)	random, 95% CI	
Burmeister et al,[12] 2005	86	128	105	128	30.3	0.45 (0.25, 0.80)	
Lee et al,[11] 2004	16	51	16	50	25.9	0.97 (0.42, 2.25)	
Lv et al,[8] 2010	51	78	75	80	22.8	0.13 (0.05, 0.35)	
Tepper et al,[7] 2008	8	30	16	26	21.0	0.23 (0.07, 0.70)	
Total (95% CI)		**287**		**284**	**100**	**0.36 (0.16, 0.79)**	
Total events	161		212				

Heterogeneity: $\tau^2=0.47$; $\chi^2=10.40$, $df=3$ ($P=0.02$); $I^2=71\%$
Test for overall effect: $Z=2.52$ ($P=0.01$)

Figure 5 Pooled analysis of PFS between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; PFS, progression-free survival; S, surgery; SA, surgery alone.

Reference	Experimental Events	Total	Control Events	Total	Weight (%)	OR M–H, random, 95% CI	OR M–H, random. 95% CI
Burmeister et al,[12] 2005	61	128	68	128	23.6	0.80 (0.49, 1.31)	
Lee et al,[11] 2004	19	51	18	50	22.1	1.06 (0.47, 2.37)	
Mariette et al,[10] 2014	28	98	43	97	23.1	0.50 (0.28, 0.91)	
Tepper et al,[7] 2008	9	30	12	26	20.4	0.50 (0.17, 1.50)	
van Hagen et al,[9] 2012	62	178	188	188	10.7	0.00 (0.00, 0.02)	
Total (95% CI)		**485**		**489**	**100**	**0.35 (0.10, 1.19)**	
Total events	179		329				

Heterogeneity: $\tau^2=1.59$; $\chi^2=43.55$, df=4 ($P<0.00001$); $I^2=91\%$
Test for overall effect: $Z=1.68$ ($P=0.09$)

Figure 6 Pooled analysis of R rate between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; R, reference; S, surgery; SA, surgery alone.

Discussion

Surgery is potentially curative in locoregionally advanced cancer, but the morbidity and mortality associated with esophagectomy has restricted its role to a minority of medically fit patients.[13] Local and distant recurrence dominates after surgical resection.[14] Refinements in surgical technique have decreased postoperative mortality, but this has not been associated with prolonged OS.[15]

Lymph node recurrence was significantly lower in the CRT group than in the SA group. This result suggests that CRT was effective for local control.

However, a limited number of phase III trials on neoadjuvant CRT followed by surgery versus SA have produced conflicting results, contributing little to justify the routine use of CRT.[16,17]

A meta-analysis had suggested that preoperative CRT may improve survival and locoregional control but that it was associated with higher toxicity and increased mortality. Radiation might contribute to the failure of an anastomotic leak and postoperative acute lung injury. Long-term survival is maximized by the use of CRT followed by surgery for locally advanced esophageal cancer. However, patients are more likely to develop toxicity.

The rationale for the addition of irradiation to chemotherapy for resectable esophagectomy is based on good evidence of downstaging the tumor and improvement of local control,[3] meaning that complete tumor resection is more probable and suboptimal surgery is less frequent. Evidently, such a downsizing effect is of greatest advantage in locally advanced tumors, where the integrity of the resection margin is more often threatened. There was a stronger benefit for better OS and PFS in the CRT-surgery arm compared with the surgery arm in this analysis. However, this study does not prove that neoadjuvant CRT improved the 3-year OS rate and 5-year OS rate, suggesting that differences in this demand further analysis.

CRT was effective for locoregional control. However, neither R rate nor M rate differed between groups $P=0.09$ and $P=0.08$, respectively. The reason for this lack of advantage in patients treated with neoadjuvant CRT can be explained in several ways. At first, there exists a publication bias for this meta might be ignored, the weaknesses of all included studies (underpowered different study design, doubtful staging accuracy and stratification, possible unbalanced randomization, variable radiation doses and its delivery, variable chemotherapy regimens and non-standardized surgical approach). In our study, the heterogeneity of the studies reporting available data on R rate was too high ($I^2=91\%$), so the true efficacy of trimodality therapy for esophageal cancer remains unclear and controversial. Second, pretrials show the effectiveness of the preoperative CRT regimen

Reference	Experimental Events	Total	Control Events	Total	Weight (%)	OR M–H, fixed, 95% CI	OR M–H, fixed, 95% CI
Burmeister et al,[12] 2005	48	128	54	128	50.9	0.82 (0.50, 1.36)	
Lee et al,[11] 2004	6	51	12	50	16.1	0.42 (0.14, 1.23)	
Mariette et al,[10] 2014	22	98	28	97	32.9	0.71 (0.37, 1.36)	
Total (95% CI)		**277**		**275**	**100**	**0.72 (0.50, 1.04)**	
Total events	76		94				

Heterogeneity: $\chi^2=1.22$, df=2 ($P=0.54$); $I^2=0\%$
Test for overall effect: $Z=1.73$ ($P=0.08$)

Figure 7 Pooled analysis of metastasis rate between CRT and SA.
Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; M–H, Mantel–Haenszel; OR, odds ratio; S, surgery; SA, surgery alone.

in patients with squamous cell cancer, and the outcome is more encouraging.[18] The doses used in our regimen might be adequate for a benefit in patients with squamous cell carcinoma; however, we cannot conclude this possibility with certainty on the basis of the subgroup analysis. So the different responses of squamous cell cancers and nonsquamous cell cancers to CRT may be a prognostic factor for survival owing to the difference in histology of the tumor type, and this should be assessed separately in future. Moreover, many studies have paid attention to molecular markers, such as epidermal growth factor receptor inhibitors[19] and cycloxygenase-2.[20] The expression level of several genes changed after neoadjuvant therapy. For example, thymidine synthesis, dihydropyrimidine dehydrogenase, glutathione S-transferase Pi, epidermal growth factor receptor, and human epidermal growth factor receptor 2 are negatively expressed.[21] Thus, whether or not the survival benefit of neoadjuvant CRT can be negated by molecular markers should be taken into consideration.

The possible benefit of neoadjuvant CRT would necessarily depend on discriminating the patients qualified and not qualified to benefit from the neoadjuvant therapy and on preventing unnecessary harm to and reducing the therapeutic expense of the treatment. As treatment regimens improve and the incidence of detection of earlier-stage disease increases,[14] improved patient compliance rates mandate an alternative approach to patients who cannot benefit from resection but are placed at risk for mortality and long-term morbidity from surgery.

A possible limitation of this study is its nonrandomized nature. We did not observe more survival differences between two groups from the unmatched analysis. The translation of outcomes into a survival benefit might be more pronounced with well-selected patients.

Conclusion

Further efforts for individualized therapy for CRT should be considered according to multiple aspects such as pathologic type of the tumor[22] and the biological and molecular markers of the tumor in order to maximize the benefit and minimize the harmful effects of neoadjuvant CRT. As therapies improve, it is likely that the toxicity may be reduced and neoadjuvant treatment may provide a more marked benefit in esophageal cancer.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Di Fiore F, Lecleire S, Rigal O, Galais MP. Predictive factors of survival in patients treated with definitive radiochemotherapy for squamous cell esophageal carcinoma. *World J Gastroenterol*. 2006;12:4185–4190.
2. Li S, Liu H, Diao C, et al. Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. *Oncotarget*. 2017;8(22):36339–36353.
3. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. *Lancet Oncol*. 2011;12:681–692.
4. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539–1558.
5. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–560.
6. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. *J Clin Oncol*. 2001;19(2):305–313.
7. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol*. 2008;26(7):1086–1092.
8. Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. *World J Gastroenterol*. 2010;16(13):1649–1654.
9. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. *N Engl J Med*. 2012; 366(22):2074–2084.
10. Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. *J Clin Oncol*. 2014;32(23):2416–2422.
11. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. *Ann Oncol*. 2004;15(6):947–954.
12. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. *Lancet Oncol*. 2005; 6(9):659–668.
13. Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in oesophageal cancer: a SEER database analysis. *J Thorac Oncol*. 2012;7(2):443–447.
14. Edgren G, Adami HO, Weiderpass Vainio E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. *Gut*. 2013;62(10): 1406–1414.
15. Barnett SA, Rizk NP. Randomized clinical trials in oesophageal carcinoma. *Surg Oncol Clin N Am*. 2010;19(1):59–80.
16. Urba SG, Orringer MB, Turrisi A, et al. A randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal cancer. *J Clin Oncol*. 2000;19:303–313.
17. Burmeister BH, Smithers BM, Fitzgerald L, et al. A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus [abstract]. *Proc Am Soc Clin Oncol*. 2002;21:130a.
18. Rizk NP, Seshan VE, Bains MS, et al. Prognostic factors after combined modality treatment of squamous cell carcinoma of the oesophagus. *J Thorac Oncol*. 2007;2(12):1117–1123.
19. Trial register NCT01107639; 2013. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01107639?term=ruhstaller&rank=1. Accessed January 31, 2013.
20. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following neoadjuvant radio-chemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. *Clin Cancer Res*. 2005;23:8341–8347.

21. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. *J Am Coll Surg*. 2005;3:336–344.

22. Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncology – multifactorial decision support systems. *Nat Rev Clin Oncol*. 2012;10:27–40.